Trastuzumab: as the comparator

90 studies: what is tested is compared with it. Page 1 of 1. Open to participants first (33), then studies with results posted, then the rest; newest registration first within each.

SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete ResponseNot yet recruitingNCT07856303Phase 2 Report a problem
A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast CancerNot yet recruitingNCT07545044Phase 2 Report a problem
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.Not yet recruitingNCT07528898Phase 2 Report a problem
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast CancerRecruitingNCT07518173Phase 3 Report a problem
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast CancerRecruitingNCT07441460Phase 3 Report a problem
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast CancerRecruitingNCT07377643Phase 3 Report a problem
RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC FailureNot yet recruitingNCT07366840Phase 2/3 Report a problem
A Study of KN026-based Combination Therapy in HER2-positive Gastric CancerNot yet recruitingNCT07332533Phase 2/3 Report a problem
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat CancerNot yet recruitingNCT07294534Phase 2/3 Report a problem
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast CancerRecruitingNCT07294508Phase 2/3 Report a problem
Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.Not yet recruitingNCT07136974Phase 2 Report a problem
A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT07118527Phase 3 Report a problem
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerRecruitingNCT07102381Phase 2 Report a problem
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast CancerRecruitingNCT07047365Phase 3 Report a problem
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerRecruitingNCT07043725Phase 3 Report a problem
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast CancerRecruitingNCT07003074Phase 3 Report a problem
JSKN003 Combined Treatment of HER2-positive Gastric CancerNot yet recruitingNCT06998771Phase 2 Report a problem
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BCRecruitingNCT06927180Phase 2 Report a problem
A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast CancerRecruitingNCT06891833Phase 2/3 Report a problem
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric CancerRecruitingNCT06764875Phase 3 Report a problem
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Phase 3 Report a problem
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)RecruitingNCT06730373Phase 2 Report a problem
A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular RelapseRecruitingNCT06643585Phase 3 Report a problem
T-DXd Versus THP for Medium-risk HER2-positive Early Breast CancerNot yet recruitingNCT06548178Phase 2 Report a problem
To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric CancerRecruitingNCT06504732Phase 2/3 Report a problem
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast CancerRecruitingNCT06435429Phase 3 Report a problem
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical TrialRecruitingNCT06278870Phase 3 Report a problem
DP303c in Patients With HER2-positive Advanced Breast CancerNot yet recruitingNCT05901935Phase 3 Report a problem
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast CancerRecruitingNCT05900206Phase 2 Report a problem
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.RecruitingNCT05838066Phase 3 Report a problem
NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast CancerRecruitingNCT05704829Phase 2 Report a problem
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland CancersRecruitingNCT05408845Phase 2 Report a problem
Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant TherapyNot yet recruitingNCT04973319Phase 3 Report a problem
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast CancerCompletedNCT05415215Phase 3Results posted Report a problem
MARGetuximab Or Trastuzumab (MARGOT)Active, not recruitingNCT04425018Phase 2Results posted Report a problem
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerCompletedNCT04082364Phase 2/3Results posted Report a problem
A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast CancerCompletedNCT04024462Phase 3Results posted Report a problem
A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast CancerCompletedNCT03674112Phase 2Results posted Report a problem
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]CompletedNCT03523585Phase 3Results posted Report a problem
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast CancerCompletedNCT03493854Phase 3Results posted Report a problem
SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast CancerCompletedNCT03262935Phase 3Results posted Report a problem
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast CancerCompletedNCT02492711Phase 3Results posted Report a problem
Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.CompletedNCT02472964Phase 3Results posted Report a problem
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast CancerTerminatedNCT02144012Phase 3Results posted Report a problem
A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerCompletedNCT02131064Phase 3Results posted Report a problem
Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With PaclitaxelCompletedNCT02073487Phase 2Results posted Report a problem
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast CancerCompletedNCT01966471Phase 3Results posted Report a problem
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)CompletedNCT01853748Phase 2Results posted Report a problem
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)CompletedNCT01772472Phase 3Results posted Report a problem
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin TreatmentCompletedNCT01125566Phase 3Results posted Report a problem
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)CompletedNCT01120184Phase 3Results posted Report a problem
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast CancerCompletedNCT01008150Phase 2Results posted Report a problem
Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast CancerCompletedNCT00915018Phase 2Results posted Report a problem
Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ PatientsCompletedNCT00841828Phase 2Results posted Report a problem
6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or TrastuzumabCompletedNCT00826267Phase 2Results posted Report a problem
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast CancerCompletedNCT00820222Phase 3Results posted Report a problem
A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic DiseaseCompletedNCT00679341Phase 2Results posted Report a problem
Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast CancerCompletedNCT00667251Phase 3Results posted Report a problem
Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast CancerCompletedNCT00429299Phase 2Results posted Report a problem
A Phase 1 Comparative Study to Evaluate Pharmacokinetics, Immunogenicity, Safety and Tolerability of Bmab3000 and Herceptin Hylecta® After a Single 600 mg SC Injection in Healthy Male VolunteersCompletedNCT07299955Phase 1 Report a problem
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast CancerActive, not recruitingNCT07196774Phase 3 Report a problem
A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction AdenocarcinomaTerminatedNCT07040059Phase 1/2 Report a problem
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast CancerActive, not recruitingNCT06747338Phase 3 Report a problem
Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast CancerCompletedNCT06107790Phase 3 Report a problem
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast CancerActive, not recruitingNCT06057610Phase 3 Report a problem
A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast CancerWithdrawnNCT05474690Phase 3 Report a problem
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer PatientsActive, not recruitingNCT05426486Phase 2/3 Report a problem
Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.CompletedNCT05301530Phase 1 Report a problem
Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer PatientsCompletedNCT05301010Phase 3 Report a problem
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Phase 3 Report a problem
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET)TerminatedNCT05063786Phase 3 Report a problem
Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®CompletedNCT04905667Phase 1 Report a problem
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)Active, not recruitingNCT04784715Phase 3 Report a problem
A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.Status unknownNCT04385563Phase 3 Report a problem
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)Active, not recruitingNCT04379596Phase 2 Report a problem
A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBCActive, not recruitingNCT04262804Phase 2 Report a problem
Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast CancerStatus unknownNCT04246502Phase 2 Report a problem
Clinical Trial of Comparative Study of GB221 PharmacokineticsCompletedNCT04175171Phase 1 Report a problem
Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for InjectionStatus unknownNCT04170595Phase 1/2 Report a problem
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast CancerTerminatedNCT04066790Phase 2 Report a problem
Pharmacokinetic, Safety and Immunogenicity Study of CMAB809 and Herceptin in Healthy VolunteersCompletedNCT04049409Phase 1 Report a problem
Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast CancerStatus unknownNCT03273595Phase 2 Report a problem
A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs HerceptinStatus unknownNCT03085368Phase 2/3 Report a problem
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UB-921 in Healthy VolunteersCompletedNCT03013881Phase 1 Report a problem
Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast CancerActive, not recruitingNCT02625441Phase 3 Report a problem
Neoadjuvant Response-guided Treatment of HER2 Positive Breast CancerActive, not recruitingNCT02568839Phase 2/3 Report a problem
A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.CompletedNCT01745965Phase 2 Report a problem
Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast CancerWithdrawnNCT01205217Phase 2 Report a problem
Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast CancerCompletedNCT00567554Phase 3 Report a problem
Phase I/II Study of Neoadjuvant Lapatinib in Breast CancerCompletedNCT00450892Phase 1/2 Report a problem

← Trastuzumab